Genome Valley in Hyderabad | Bio Asia Telangana life Sciences | BioAsia

About BioAsia

Genome Valley

Genome Valley, spread over 600 sq. kms. in the vicinity of Hyderabad (the Cyber City of India) is India's first world-class biotech cluster for biotech research, training, collaboration and manufacturing activities. With an established presence of several global and Indian biotechnology companies, globally renowned research institutions, and best-in-class supporting specialized infrastructure, today Genome Valley is the largest and most vibrant biotech cluster in the country. The presence of CCMB, ICRISAT, IICT, NIN, CDNAFP, GVK Lifesciences, etc. will provide strength and sustenance for the biotech cluster. The Shameerpet cluster of the Genome Valley is India's first systematically developed biotech cluster, boasting of

world-class infrastructure facilities in the form of Industrial / Knowledge Parks, Special Economic Zones (SEZs), Multi-tenanted wet laboratories and Incubation facilities. The cluster synergizes a healthy mix of companies in the realm of agri biotech, CRM, biopharma, vaccine manufacturing, regulatory and testing and other related areas.

Genome Valley Comprises of:

www.iciciknowledgepark.com	Committed to facilitating business driven research & development Spread across 200 acres and has over 30 R&D units functioning. Prominent Companies: GVK Bio, Aptuit Laurus, Nectar Therapeutics, Dupont India Pvt Ltd, etc.

www.labspace.com	Total area of 300 acres featuring an innovation corridor at an area of 140,000 sft Prominent Companies: Vimta Labs, Biological E, Uni-Sankyo Ltd, ITC Ltd, Genotex Intl (India), etc

www.apiic.in	Launched for expanding the potential of bulk drugs and pharmaceutical industry in the state Spread over 600 acres and features 2 biotech SEZs

www.labspace.com	World class integrated science park 300,000 Sft of best in class turnkey laboratory & office space India's most advanced R&D infrastructure and laboratory buildings

www.labspace.com	A PPP initiative between Alexandria and Department of Biotechnology (Govt. of India), Council of Scientific & Industrial Research (Govt. of India) & APIIC (Govt. of AP) State of the art cGMP pilot plant facility; cell culture (30L), microbial (20L, 200L), etc.

	Archives
	Gallery
	Publications

Industry Speak

Dr. Seth Berkley, CEO, GAVI Alliance

India is a prime example of how the vaccine landscape has changed over the past 20 years....

Dr. Krishna M. Ella, CMD, Bharat Biotech International Ltd., Hyderabad

BioAsia over the years has been instrumental in showcasing the Lifesciences and R&D strengths of Hyderabad and Andhra Pradesh to ...

Dr. K V Balasubramaniam, Managing Director, Indian Immunologicals Ltd.

More professionally conducted this time with better industry participation

Dr. KV Raghavan, VP, FABA

"Indian Biotech industry had crossed over 3$ billion in 2010-2011 and BioAsia is an integral part of the Biotech industry's growth."

Dr. Krishna M. Ella, CMD, Bharat Biotech International Ltd., Hyderabad

BioAsia over the years has been instrumental in showcasing the Lifesciences and R&D strengths of Hyderabad and Andhra Pradesh ...

Vishal Gandhi, SVP and Head- Life Sciences, Yes Bank

"It was a truly a vibrant platform and discussions were very stimulating clearly suggesting a road map to take the Indian biotech industry to next level of growth."

Roopesh Bhargava, Director - Sales & Marketing, Sanofi Pasteur India (Pvt) Ltd., Mumbai

"It was indeed a pleasure attending the BioAsia 2012 at Hyderabad. It was a very well thought off coordinated effort to put such a conference. My personal compliments to the team. The Agenda and the subject was very well chosen"

Dr. Shreemanta K Parida, CEO, Vaccine Grand Challenge Program, Dept of Biotechnology, Ministry of Science & Technology, Govt. of India

I commend BioAsia2012 organisers for making an effort to bring various stakeholders around the table in a breakfast meeting with Seth Berkley ...

Dr. Harish Iyer, CEO, Shantha Biotech, Hyderabad

"This was an excellent meeting with topics discussed being clearly relevant to vaccines and expanding use for improvement of public health"

Mr. Manni Kantipudi, Chief Executive Officer, GVK Biosciences

"The BioAsia 2012 was well organized, had good speakers and was well attended. The focus on CROs was important for HYDERABAD to project".

Dr. K V Balasubramaniam, Managing Director, Indian Immunologicals Ltd.

"More professionally conducted this time with better industry participation"

Mr. Karikal Valaven, IAS, Convener, BioAsia 2012

The precise number of registered delegates for the event was 598; in addition over 450 visitors also thronged the three-day global bio-business event ...

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech International Ltd.

Over the years, BioAsia has become an industry oriented event while the Bangalore India Bio event has remained research oriented ...

Dr. Richard Connell, Vice President and Head of Asia Research, Pfizer, Shanghai

"There were some interesting discussions and it was good to meet business partners at the location. The logistics (layout of rooms, food, location) were all very comfortable."

Mr. Sai D. Prasad, VP – Business Development, Bharat Biotech International Ltd.

"BioAsia 2012 was well organized."

BioAsia Organizers

faba

Pharmexcil

govt-ap-img

Click on logo...